AstraZeneca Q2 results lifted by sales of new drugs
AstraZeneca raised its second quarter product sales forecast and had strong sales from its cancer medicines. Sales from its oncology unit shot up to $2.17 billion and the top-selling lung cancer drug nearly doubled to $784 million. Yahoo Finance’s Dan Roberts, Kristin Myers and Sibile Marcellus discuss today’s trending ticker.